Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
B&A Oncomedical maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, the company has 1 pending office action requiring a response. This single active matter suggests a concentrated prosecution phase for the company's current intellectual property.
The portfolio is managed through a structure involving 1 distinct examiner and 1 distinct art unit. Having 1 distinct examiner and 1 distinct art unit indicates that the company's applications are currently localized within a specific technical niche at the patent office. Practitioners can expect a consistent examination environment due to the lack of departmental or personnel variety in the current cycle.
SEITZ, ANTHONY JOSEPH is identified as the busiest examiner for this portfolio. This individual is responsible for the 1 busiest examiner pending office action. Because this examiner handles the entirety of the company's pending workload, the outcome of this specific interaction will define the immediate success of the portfolio. The concentration of work under SEITZ, ANTHONY JOSEPH allows for a focus on this examiner's specific preferences and historical patterns.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18361284 | COMBINATION OF COMPOUNDS FOR USE IN THERAPY | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18361284 | COMBINATION OF COMPOUNDS FOR USE IN THERAPY | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18361284 | COMBINATION OF COMPOUNDS FOR USE IN THERAPY | SEITZ, ANTHONY JOSEPH | 1629 | §102§103§112 | Non-Final OA | — | Pending | Jul 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialB&A Oncomedical has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anthony Joseph Seitz has the most, with 1 of B&A Oncomedical's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
